Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
EPS (Diluted)
Antengene Corporation Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
EPS (Diluted)
¥0
|
CAGR 3-Years
57%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
¥5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's EPS (Diluted)?
EPS (Diluted)
-0.9
CNY
Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's EPS (Diluted) amounts to -0.9 CNY.
What is Antengene Corporation Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-34%
Over the last year, the EPS (Diluted) growth was 3%. The average annual EPS (Diluted) growth rates for Antengene Corporation Ltd have been 57% over the past three years , -34% over the past five years .
You don't have any saved screeners yet